文献速递心律失常血脂与心血管预防

女性是房颤卒中风险修饰因素而非独立风险因素:是否应采用CHA2DS2-VA评分替代CHA2DS2-VASc?

Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc?
PubMed 文献 · Circulation · 2018-01-01

该研究基于3个全国性注册队列,纳入1997至2015年新发非瓣膜性房颤患者239 671例(女性48.7%),排除基线口服抗凝治疗者。结果显示女性整体1年血栓栓塞率为7.3/100人年,男性为5.7/100人年;CHA2DS2-VA评分0分时男女1年绝对风险均为0.5%,评分>5分时风险>7%。女性与CHA2DS2-VA评分的交互作用显著(P<0.001),提示女性是卒中风险修饰因素而非独立风险因素。

要点

  • 女性是房颤卒中的风险修饰因素,而非独立风险因素。
  • 初始抗凝决策可基于CHA2DS2-VA评分(不含性别项)。
  • 女性在≥2个额外卒中风险因素时,性别项修饰并加重卒中风险。

核心结论

  • 女性是房颤患者卒中的风险修饰因素,而非整体风险因素。
  • 初始口服抗凝治疗决策可基于CHA2DS2-VA评分(即排除性别类别标准)进行指导。
  • 性别类别风险成分修饰并加重了因≥2个额外卒中风险因素而符合口服抗凝治疗女性的卒中风险。

研究设计与样本

  • 排除基线接受口服抗凝治疗者,随访至治疗启动时删失,在丹麦国家患者注册中随访最多1年。
  • 共纳入239 671例房颤患者(女性48.7%),女性平均年龄76.6岁、男性70.3岁,女性平均CHA2DS2-VA评分2.7、男性2.3。

主要发现

  • 女性总体1年血栓栓塞率为7.3/100人年,男性为5.7/100人年。
  • CHA2DS2-VA评分0分的男性和女性1年血栓栓塞绝对风险均为0.5%。
  • CHA2DS2-VA评分>5分的合并症较多患者1年绝对风险>7%。
  • 以男性为参照,评分>1分各点风险比显示女性卒中风险更高,交互作用P<0.001。

临床怎么用

  • 初始口服抗凝治疗决策可基于CHA2DS2-VA评分(不含性别项)进行指导。
  • 对于因≥2个额外卒中风险因素而符合口服抗凝治疗的女性,性别项修饰并加重其卒中风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stroke risk in atrial fibrillation is assessed by using the CHA2DS2-VASc score. Sex category (Sc, ie, female sex) confers 1 point on CHA2DS2-VASc. We hypothesized that female sex is a stroke risk modifier, rather than an overall risk factor, when added to a CHA2DS2-VA (sex-independent thromboembolism risk) score scale. METHODS: Using 3 nationwide registries, we identified patients with incident nonvalvular atrial fibrillation from January 1, 1997, through December 31, 2015. Patients receiving oral anticoagulant treatment at baseline were excluded, and person-time was censored at the time of treatment initiation (if any). CHA2DS2-VA scores were calculated for men and women, and were followed for up to 1 year in the Danish National Patient Registry. The primary outcome was a primary hospital code for ischemic stroke or systemic embolism (thromboembolism). We calculated crude event rates for risk strata as events per 100 person-years. For quantifying absolute risk of stroke, we calculated risks based on the pseudovalue method. Female sex as a prognostic factor was investigated by inclusion as an interaction term on the CHA2DS2-VA score to calculate the thromboembolic risk ratio for different score points. RESULTS: A total of 239 671 patients with atrial fibrillation (48.7% women) contributed to the analyses. The mean ages for women and men were 76.6 years and 70.3 years, respectively; the mean CHA2DS2-VA scores were 2.7 for women and 2.3 for men. The overall 1-year thromboembolic rate per 100 person-years for women was 7.3 and 5.7 for men. The 1-year absolute risk of thromboembolism was 0.5% among men and women with a CHA2DS2-VA score of 0 and increased up to >7% among very comorbid patients (score >5). The risk ratio (male as reference) across points >1 indicated that women exhibit a higher stroke risk. The interaction was statistically significant (P<0.001). CONCLUSIONS: Female sex is a risk modifier for stroke in patients with atrial fibrillation. Initial decisions on oral anticoagulant treatment could be guided by a CHA2DS2-VA score (ie, excluding the sex category criterion), but the Sc risk component modifies and accentuates stroke risk in women who would have been eligible for oral anticoagulant treatment on the basis of ≥2 additional stroke risk factors.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Nielsen PB, Skjøth F, Overvad TF, et al. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? Circulation. 2018. PMID: 29459469. doi:10.1161/CIRCULATIONAHA.117.029081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。